Amgen Surpasses Expectations with Strong Q2 Results and Raised Guidance
Amgen reported strong Q2 earnings exceeding expectations but saw declines in key product sales, leading to a drop in after-hours stock trading. The company highlighted growth in products like Uplizna and Tepezza, and raised its full-year guidance despite mixed quarterly results.